In short-term ex vivo experiments with bone marrow samples from MM patients, daratumumab-mediated lysis was mainly associated with the CD38 expression levels on MM cells and the effector-to-target ratio, but not with PD-L1 expression levels or proportion of PD-1+ T-cells. This evidence concerns the gene CD38 and Miyoshi myopathy.